SWOG
Agendia, NCI, SWOG to Study Neoadjuvant Immunotherapy, Chemo in High-Risk Breast Cancer Patients
The SWOG Trial S2206 will enroll hormone receptor-positive breast cancer patients with aggressive tumors as determined by Agendia's 70-gene expression assay.